Physician profile
Richard Walker
NPI 1497892996
$5,605.01
in general payments reported to CMS, 2019-2025
27 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $411 · 2021: $501 · 2022: $825 · 2023: $827 · 2024: $1,147 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,020.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,153.00 | 2019-2025 | Cequa |
| Alcon Vision LLC | $883.17 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb Americas INC. | $858.56 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Coopervision INC. | $687.40 | 2019-2024 | Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $242.81 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $209.40 | 2020-2025 | |
| Sight Sciences, INC. | $190.06 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Novartis Pharmaceuticals Corporation | $162.21 | 2019-2022 | |
| Glaukos Corporation | $147.73 | 2024 | Idose |
| Harrow Eye, LLC | $134.84 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $119.55 | 2022-2025 | Dextenza |
| Allergan, INC. | $113.82 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $110.25 | 2021-2022 | |
| Oyster Point Pharma, INC. | $104.64 | 2022-2024 | Tyrvaya |
| Biotissue Holdings INC. | $88.66 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $74.20 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $69.17 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $51.68 | 2022-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $43.72 | 2020 | |
| Amgen INC. | $32.38 | 2025 | Tepezza |
| Abbvie INC. | $28.57 | 2022 | |
| Horizon Therapeutics Plc | $27.49 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $18.18 | 2025 | Iyuzeh |
| Alcon Research LLC | $12.07 | 2019 | |
| Shire North American Group INC | $11.83 | 2019 | |
| Lkc Technologies, INC. | $10.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.